Advertisement
UK markets closed
  • FTSE 100

    7,682.50
    +52.48 (+0.69%)
     
  • FTSE 250

    19,354.38
    +299.51 (+1.57%)
     
  • AIM

    741.31
    +4.81 (+0.65%)
     
  • GBP/EUR

    1.1668
    -0.0013 (-0.11%)
     
  • GBP/USD

    1.2655
    +0.0029 (+0.23%)
     
  • Bitcoin GBP

    49,152.45
    +437.84 (+0.90%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,137.08
    +40.81 (+0.80%)
     
  • DOW

    39,087.38
    +90.99 (+0.23%)
     
  • CRUDE OIL

    79.81
    +1.55 (+1.98%)
     
  • GOLD FUTURES

    2,091.60
    +36.90 (+1.80%)
     
  • NIKKEI 225

    39,910.82
    +744.63 (+1.90%)
     
  • HANG SENG

    16,589.44
    +78.00 (+0.47%)
     
  • DAX

    17,735.07
    +56.88 (+0.32%)
     
  • CAC 40

    7,934.17
    +6.74 (+0.09%)
     

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion Oyj
Orion Oyj

ORION CORPORATION
STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS
2 MAY 2023 at 16.15 EEST

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds increased on 1 May 2023 above five (5) per cent of Orion Corporation’s total shares.

Total positions of BlackRock, Inc. and its funds subject to notification:

 

% of shares and voting rights
(total of point A)

% of shares and voting rights through financial instruments
(total of point B)

Total of both in % (points A + B)

Total number of shares and voting rights of issuer

Resulting situation on the date on which threshold was crossed or reached

4.94% shares

 

Below 5% voting rights

0.09% shares

 

Below 5% voting rights

5.03% shares

 

Below 5% voting rights

141,134,278 shares

 

787,749,536 voting rights

Position of previous notification (if applicable)

Below 5% shares

 

Below 5% voting rights

Below 5% shares

 

Below 5% voting rights

Below 5% shares

 

Below 5% voting rights

 

Notified details of the resulting situation on the date on which the threshold was crossed:

Point A: Shares and voting rights:

Class/type of shares
ISIN code

Number of shares and voting rights

% of shares and voting rights

 

Direct (SMA 9:5)

Indirect (SMA 9:6 and 9:7)

Direct (SMA 9:5)

Indirect (SMA 9:6 and 9:7)

FI0009014377

 

6,972,993 shares

 

Below 5% voting rights

 

4.94% shares

 

Below 5% voting rights

POINT A SUBTOTAL

6,972,993 shares

 

Below 5% voting rights

4.94% shares

 

Below 5% voting rights

Point B: Financial instruments according to SMA 9:6a:

Type of financial instrument

Expiration date

Exercise / Conversion Period

Physical or cash settlement

Number of shares and voting rights

% of shares and voting rights

Securities Lent

N/A

N/A

Physical

133,020 shares

 

Below 5% voting rights

0.09% shares

 

Below 5% voting rights

CFD

N/A

N/A

Cash

5,725 shares

 

Below 5% voting rights

0.00% shares

 

Below 5% voting rights

 

 

 

POINT B SUBTOTAL

138,745 shares

 

Below 5% voting rights

0.09% shares

 

Below 5% voting rights

Orion Corporation

Liisa Hurme

President and CEO

   

Olli Huotari

SVP, Corporate Functions

 


Contact person:
Tuukka Hirvonen, Investor Relations, Orion Corporation
tel. +358 10 426 2721

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.